In the present case, cephalexin was administered in the presence of viral symptoms, which may have resulted in excessive activation of CD4+ and CD8+ T-cells due to the viral infection, coupled with an immune response to the drug, ultimately leading to AGEP onset. The gene discussed is CD4; the disease is viral infectious disease.